4c Biomed

Executive Summary

4C Biomed is a UK-based biotechnology company leveraging a patient-derived discovery platform to identify novel immuno-oncology targets. Founded in 2017 and headquartered in Oxford, the company focuses on developing first-in-class antibody therapies. Its lead program, anti-4CB1, is a monoclonal antibody targeting HVEM, a checkpoint receptor in the TNF receptor superfamily. The company plans to file an IND and initiate Phase I clinical trials in 2026, targeting solid tumors. 4C Biomed's platform enables the identification of previously unexplored immune targets by functionally screening patient samples, potentially uncovering more effective cancer immunotherapies. While still preclinical, the lead candidate's novel mechanism and the company's unique discovery approach position it as an emerging player in the IO space, albeit with typical early-stage risks including funding dependence and clinical execution challenges.

Upcoming Catalysts (preview)

• Q4 2026IND Filing / Initiation of Phase I Clinical Trial70% success
• Q3 2026Presentation of Preclinical Data at Major Oncology Conference80% success
• TBDPartnership or Licensing Deal for Platform Technology30% success